Immunotherapy for childhood warts.
Treatment-resistant warts are a common and frustrating problem for patients, parents, and providers alike. No wart treatment is uniformly effective. Indeed, well-designed randomized controlled trials are sorely needed to establish the true efficacy of all wart therapies. Treatment should be tailored to each individual patient. Although none of the immunologically-based treatments listed above (see Table, page 377) is FDA-approved for warts, they provide the treating physician with options for patients with warts that are resistant to standard treatments.
Dasher
David A
DA
Department of Dermatology, UNC Chapel Hill, USA. david_dasher@med.unc.edu
Burkhart
Craig N
CN
Morrell
Dean S
DS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000941:Antigens / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002927:Cimetidine / Q000627:therapeutic use; D003503:Cyclobutanes / Q000627:therapeutic use; D003521:Cyclopropanes / Q000627:therapeutic use; D004137:Dinitrochlorobenzene / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007167:Immunotherapy / Q000379:methods*; D015552:Injections, Intralesional; D007509:Irritants / Q000627:therapeutic use; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000941:Antigens; D003503:Cyclobutanes; D003521:Cyclopropanes; D004137:Dinitrochlorobenzene; D006635:Histamine H2 Antagonists; D007509:Irritants; C020637:squaric acid dibutyl ester; D002927:Cimetidine; C029402:diphenylcyclopropenone; D000077271:Imiquimod